Ignite Creation Date:
2025-12-24 @ 3:56 PM
Ignite Modification Date:
2025-12-26 @ 1:58 PM
Study NCT ID:
NCT01467492
Status:
TERMINATED
Last Update Posted:
2015-08-03
First Post:
2011-11-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-01
Start Date Type:
None
Primary Completion Date:
2014-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-05
Completion Date Type:
ACTUAL
First Submit Date:
2011-11-03
First Submit QC Date:
None
Study First Post Date:
2011-11-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2015-06-01
Results First Submit QC Date:
None
Results First Post Date:
2015-06-16
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-07-13
Last Update Post Date:
2015-08-03
Last Update Post Date Type:
ESTIMATED